• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

SimonMed Imaging Launches AI-Powered Personalized Breast Cancer Detection Program

by Jasmine Pennic 01/21/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– SimonMed Imaging, a provider of outpatient medical imaging services in the United States, today announced the nationwide launch of its AI-enabled Personalized Breast Cancer Detection (PBCD) program. 

– The program offers women a more comprehensive and personalized approach to breast cancer screening, empowering them to make informed decisions about their health.

PBCD Program Costs

For a cost of $40, patients can add the PBCD program to their screening 3D AI-enhanced mammogram. The program provides a personalized risk assessment, detailed breast density recommendations, and a tailored action plan outlining screening frequency and supplemental exams. This valuable information helps patients and their physicians make proactive decisions about breast health management.

The PBCD program offers several key benefits to patients:

  • Faster results: AI algorithms help expedite the analysis of mammograms, providing patients with quicker results and reducing anxiety.
  • Personalized risk assessment: The program analyzes individual risk factors to provide a personalized breast cancer risk score.
  • Detailed breast density recommendations: Provides information about breast density, a key factor in breast cancer risk.
  • Tailored action plan: Outlines personalized recommendations for screening frequency and supplemental exams, such as breast MRI or ultrasound.

 “SimonMed has offered AI technology in all 3D Mammograms to enhance breast cancer detection since 2019. Unlike other imaging centers, we offer this service at no additional cost to patients and will continue to do so,” said Dr. John Simon, CEO and Founder of SimonMed. “With PBCD, we’re taking AI enhanced Mammogram screening a step further by offering patients the option to have a timely, personalized risk assessment that considers each patient’s unique health profile. This comprehensive approach ensures that patients receive tailored recommendations for further screening, empowering them with the right care including ultrasound or MRI based on their individual risk levels. We know adding ultrasound or MRI to AI enhanced mammography with an individualized approach can more than double early detection. Our AI-driven platform is designed to help patients, and their healthcare providers, make more informed decisions, enhancing early detection and improving outcomes.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Breast Cancer, Medical Imaging Cloud, radiology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Redesign Health Study: 71% of Health Systems Adopt an "Epic-First" AI Purchasing Strategy

Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy

iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

M&A: iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

mount-sinai-launches-epic-chart-with-art-nursing-ambient-ai

Mount Sinai Medical Center Extends Epic’s Ambient AI to Inpatient Nursing

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |